Chemically modified antisense oligonucleotide against ARL4C inhibits primary and metastatic liver tumor growth

Takeshi Harada, Shinji Matsumoto, Suguru Hirota, Hirokazu Kimura, Shinsuke Fujii, Yuuya Kasahara, Hidetoshi Gon, Toshihiko Yoshida, Tomoo Itoh, Naotsugu Haraguchi, Tsunekazu Mizushima, Takehiro Noda, Hidetoshi Eguchi, Satoshi Nojima, Eiichi Morii, Takumi Fukumoto, Satoshi Obika, Akira Kikuchi

Research output: Contribution to journalArticlepeer-review

35 Citations (Scopus)


ADP-ribosylation factor-like 4c (ARL4C) is identified as a small GTP-binding protein, which is expressed by Wnt and EGF signaling and plays an important role in tubulogenesis of cultured cells and the ureters. ARL4C is little expressed in adult tissues, but it is highly expressed in lung cancer and colorectal cancer and shown to represent a molecular target for cancer therapy based on siRNA experiments. This study revealed that ARL4C is highly expressed in primary hepatocellular carcinoma (HCC) tumors and colorectal cancer liver metastases, and that ARL4C expression is associated with poor prognosis for these cancers. Chemically modified antisense oligonucleotides (ASO) against ARL4C effectively reduced ARL4C expression in both HCC and colorectal cancer cells and inhibited proliferation and migration of these cancer cells in vitro. ARL4C ASOs decreased the PIK3CD mRNA levels and inhibited the activity of AKT in HCC cells, suggesting that the downstream signaling of ARL4C in HCC cells is different from that in lung and colon cancer cells. In addition, subcutaneous injection of ARL4C ASO was effective in reducing the growth of primary HCC and metastatic colorectal cancer in the liver of immunodeficient mice. ARL4C ASO accumulated in cancer cells more efficiently than the surrounding normal cells in the liver and decreased ARL4C expression in the tumor. These results suggest that ARL4C ASO represents a novel targeted nucleic acid medicine for the treatment of primary and metastatic liver cancers.

Original languageEnglish
Pages (from-to)602-612
Number of pages11
JournalMolecular cancer therapeutics
Issue number3
Publication statusPublished - Mar 2019

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chemically modified antisense oligonucleotide against ARL4C inhibits primary and metastatic liver tumor growth'. Together they form a unique fingerprint.

Cite this